Menu
Back to Journals » Clinical Ophthalmology » Volume 12
A Phase II /III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
Authors Tauber J , Schechter BA, Bacharach J, Toyos MM , Smyth-Medina R, Weiss SL , Luchs JI
Received 3 December 2018
Accepted for publication 3 December 2018
Published 14 December 2018 Volume 2018:12 Pages 2637—2638
Tauber J, Schechter BA, Bacharach J, et al. Clin Ophthalmol. 2018;12:1921–1929.
On page 1924, Efficacy end points, Conjunctival staining section, the sentence “Statistically significant reductions in the mean change from baseline in the study eye at Day 84 relative to vehicle were observed for both OTX-101 concentrations (P<0.01). The results by study visit are depicted in Figure 3.” should read “Statistically significant reductions in the least squares mean change from baseline in the study eye at Day 84 relative to vehicle were observed for both OTX-101 concentrations (P<0.01). The results by study visit are depicted in Figure 3.”
Read the original article
Further corrigendum has been published
© 2018 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.